Trial · NCT06927128
Neoadjuvant Chemotherapy in High - Risk Upper Tract Urothelial Carcinoma
NCT06927128, Phase 2, Not yet recruiting, Changhai Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Neoadjuvant Chemotherapy in High - Risk Upper Tract Urothelial Carcinoma. Trials, record NCT06927128. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06927128
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Neoadjuvant Chemotherapy in High - Risk Upper Tract Urothelial Carcinoma
- NCT number
- NCT06927128
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 45 participants, estimated
- Lead sponsor
- Changhai Hospital
- Conditions
- UTUC, NAC
- Interventions
- Gemcitabine, Cisplatin
- First posted
- 2025-04-15
- Last updated
- 2025-04-15
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pathological response rate（pRR） | At the time of pathological report issuance，approximately within 7-10 business days after surgery | defined as postoperative pathology \<ypT2N0 |
| Secondary | Pathological complete response rate (pCR) | At the time of pathological report issuance，approximately within 7-10 business days after surgery | defined as postoperative pathology \<ypT1N0 |
| Secondary | Imaging response rate | From the date of the first chemotherapy administration until 2 weeks after the last chemotherapy session, assessed up to 11-14 weeks. | defined as tumor size reduction observed on imaging comparisons between pre- and post-chemotherapy assessments, with any decrease classified as a positive response.Tumor size reduction, measured as the change in the longest diameter of the primary tumor via computed tomography (CT) scan according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines. |
| Secondary | Surgery completion rate | From chemotherapy initiation to surgical resection.Patients should undergo definitive surgery within 6 weeks ( ± 2 weeks) following completion of neoadjuvant chemotherapy | Proportion of patients undergoing surgery |
| Secondary | Overall survival (OS) | From the date of surgery until the date of death or loss to follow-up, with a maximum follow-up period of 2 years. | defined as the duration from the date of surgical resection to the occurrence of death from any cause |
| Secondary | Cancer - specific survival (CSS) | From the date of diagnosis until the date of death from urothelial carcinoma or last documented follow-up, with a maximum follow-up period of 2 years. | defined as the time from diagnosis to death directly attributable to the primary cancer or its metastases, excluding mortality from unrelated causes |
| Secondary | Recurrence - free survival (RFS) | From the date of surgical resection until the date of disease recurrence (radiographically or pathologically confirmed) or death from any cause, whichever occurs first, with a maximum follow-up of 2 years. | defined as the time from post-surgery to the first documented evidence of local/regional recurrence, distant metastasis, or death from any cause, whichever occurs first |
| Other | the efficacy by detecting the chromosomal instability (CIN) of blood and urine exfoliated cell DNA | From the time of collecting the first blood and urine specimens until the time of collecting blood and urine specimens before surgery, assessed up to 15-18 weeks. | Predicting the efficacy by detecting the chromosomal instability (CIN) of blood and urine exfoliated cell DNA |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06927128
GET https://conductscience.org/api/trials/v1/NCT06927128/registered